TRVI
Trevi Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$13.56Close
$1.7BMarket cap
$9.99 – $19.5052-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 46 · weaker than 54% of stocks over 12 months
- Far from its high 30% below its 52-week high
- Distribution down-day volume 2.6× up-day volume over 50 sessions
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
30%
1wk
up 7.5%
price change
1mo
down 5.3%
price change
12-month return
up 21%
market up 11% ·
its own up 17%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
9.5×
price / book
Earnings yield
down 2.9%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 30%
return on equity
Free cash margin
—
-$42.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.7%
$0.64 a day · 2×ATR $12.27
RS
46 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.38
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 37.1% over the year, from 94m to 128m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$32.5M | -$32.5M | -$29.9M | -$33.9M | -$51.5M | -$49.3M |
| Net income | -$32.8M | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| Earnings per share | — | -$1.49 | -$0.45 | -$0.29 | -$0.47 | -$0.32 |
| Free cash flow | -$29.0M | -$28.9M | -$28.3M | -$31.8M | -$38.3M | -$42.1M |
| Cash | $45.0M | $36.8M | $12.6M | $32.4M | $34.1M | $18.9M |
| Long-term debt | $14.0M | $8.7M | $2.2M | — | — | — |
| Shareholders' equity | $27.3M | $17.1M | $107.5M | $82.5M | $99.6M | $183.2M |
| Shares outstanding | 18.55m | 28.51m | 59.94m | 68.28m | 93.60m | 128.31m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Mar 17, 2026 | Annual ↗ | Dec 31, 2025 | 76d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 20, 2024 | Annual ↗ | Dec 31, 2023 | 80d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 4, 2026 | Charter or bylaws · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Apr 17, 2026 | Material agreement · Results · Other events ↗ |
| Mar 17, 2026 | Results ↗ |
| Mar 9, 2026 | Other events ↗ |
| Dec 5, 2025 | Director or officer change ↗ |
| Nov 13, 2025 | Results ↗ |
| Aug 20, 2025 | Director or officer change ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 17, 2025 | Director or officer change · Shareholder vote ↗ |
| Jun 4, 2025 | Material agreement · Other events ↗ |